TScan Therapeutics, Inc. (TCRX)

♥ 565 Thanks from members

TScan Therapeutics, Inc. (TCRX) exhibits a polarized market profile, driven by clinical momentum in its Phase 3 ALLOHA-2 study and positive Cohort C data, counterbalanced by going-concern warnings, tightening cash reserves extending only into early 2027, and a sub-dollar share price.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →

Other Nasdaq Tickers

NASDAQ

Microchip Technology Incorporated (MCHP)

NASDAQ

Direxion Daily AAPL Bear 1X ETF (AAPD)

NASDAQ

Ascentage Pharma Group International - American Depository Shares (AAPG)

NASDAQ

Direxion Daily AAPL Bull 2X ETF (AAPU)

NASDAQ

Alpha Blue Capital US Small-Mid Cap Dynamic ETF (ABCS)

NASDAQ

AbCellera Biologics Inc. - Common Shares (ABCL)

Entity & Market Metadata

Sector: Healthcare Industry: Biotechnology Founder: Paul Keung Founder: David Baltimore Leadership: Hagen Munk (CEO) Leadership: Debbie McPherson (CBO) Leadership: Jonathan Terrett (CSO) Holder: Sanofi Holder: The Vanguard Group Holder: BlackRock Inc. Holder: RA Capital Management ImmTCR platform TCR-T cell therapies Pipeline for cancer and autoimmune diseases #TScan Therapeutics #TCRX #T-cell therapy #immunotherapy biotech #cancer pipeline